Skip to main content
Have a personal or library account? Click to login
Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel Cover

Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel

Radiology and Oncology
Volume 49 (2015): Issue 4 (December 2015)
By: ,  ,   and    
Open Access
|Nov 2015
References

References

  1. 1. Jespersen CG, Norgaard M, Borre M. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study.2014;704-9.
    Open DOISearch in Google Scholar
  2. 2. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.2005;6410-17.
    Open DOISearch in Google Scholar
  3. 3. Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.2006;4448-56.
    Open DOISearch in Google Scholar
  4. 4. Templeton AJ, Vera-Badillo FE, Wang L, Attalla M, Gouveia P, Leibowitz-Amit R, et al. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials.2013;2972-77.
    Open DOISearch in Google Scholar
  5. 5. Piccirillo JF, Vlahiotis A, Barrett LB, Flood KL, Spitznagel EL, Steyerberg EW. The changing prevalence of comorbidity across the age spectrum.2008;124-32.
    Open DOISearch in Google Scholar
  6. 6. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.2004;1502-12.
    Open DOISearch in Google Scholar
  7. 7. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.2004;1513-20.
    Open DOISearch in Google Scholar
  8. 8. Horgan AM, Seruga B, Pond GR, Alibhai SM, Amir E, De Wit R, et al. Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial.2014;119-26.
    Open DOISearch in Google Scholar
  9. 9. Chao HH, Mayer T, Concato J, Rose MG, Uchio E, Kelly WK. Prostate cancer, comorbidity, and participation in randomized controlled trials of therapy.2010;566-8.
    Open DOISearch in Google Scholar
  10. 10. Harris V, Lloyd K, Forsey S, Rogers P, Roche M, Parker C. A population-based study of prostate cancer chemotherapy.2011;706-8.
    Open DOISearch in Google Scholar
  11. 11. Lund L, Borre M, Jacobsen J, Sorenson HT, Norgaard M. Impact of comorbidity on survival of Danish prostate cancer patients, 1995-2006: a population-based cohort study.2008;1258-62.
    Open DOISearch in Google Scholar
  12. 12. Albertsen PC, Moore DF, Shih W, Lin Y, Lu-Yao GL. Impact of comorbidity on survival among men with localized prostate cancer.2011;1335-41.
    Open DOISearch in Google Scholar
  13. 13. Daskivich TJ, Chamie K, Kwan L, Labo J, Dash A, Greenfield S, et al. Comorbidity and competing risks for mortality in men with prostate cancer.2011;4642-50.
    Open DOISearch in Google Scholar
  14. 14. Halabi S, Kelly WK, George DJ, Morris MJ, Kaplan EB, Small EJ. Comorbidities predict overall survival (OS) in men with metastatic castrate-resistant prostate cancer. [Abstract].2011;abstr 189.
    Open DOISearch in Google Scholar
  15. 15. Goyal J, Pond GR, Galsky MD, Hendricks R, Small A, Tsao CK, et al. Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer.2014;36. e27-34.
    Open DOISearch in Google Scholar
  16. 16. Alibhai SM, Leach M, Tomlinson GA, Krahn MD, Fleshner NE, Naglie G. Is there an optimal comorbidity index for prostate cancer?2008;1043-50.
    Search in Google Scholar
  17. 17. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index.1994;1245-51.
    Open DOISearch in Google Scholar
  18. 18. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry.2004;2441-7.
    Open DOISearch in Google Scholar
  19. 19. Italiano A, Ortholan C, Oudard S, Pouessel D, Gravis G, Beuzeboc P, et al. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer.2009;1368-75.
    Open DOISearch in Google Scholar
  20. 20. Vickers MM, Powell ED, Asmis TR, Jonker DJ, Hilton JF, O’Callaghan CJ, et al. Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo.2012;1434-42.
    Open DOISearch in Google Scholar
  21. 21. Asmis TR, Powell E, Karapetis CS, Jonker DJ, Tu D, Jeffery M, et al. Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)--results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care.2011;118-26.
    Open DOISearch in Google Scholar
  22. 22. Droz JP, Aapro M, Balducci L, Boyle H, Van den Broeck T, Cathcart P, et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology.2014;e404-14.
    Open DOISearch in Google Scholar
  23. 23. Donze J, Lipsitz S, Bates DW, Schnipper JL. Causes and patterns of readmissions in patients with common comorbidities: retrospective cohort study.2013;f7171.
    Open DOISearch in Google Scholar
  24. 24. Hernandez C, Jansa M, Vidal M, Nunez M, Bertran MJ, Garcia-Avmerich J, et al. The burden of chronic disorders on hospital admissions prompts the need for new modalities of care: a cross-sectional analysis in a tertiary hospital.2009;193-202.
    Open DOISearch in Google Scholar
  25. 25. Zauderer MG, Sima CS, Korc-Grodzicki B, Kris MG, Krug LM. Toxicity of initial chemotherapy in older patients with lung cancers.2013;64-70.
    Open DOISearch in Google Scholar
  26. 26. Aparicio T, Jouve JL, Teillet L, Gargot D, Subtil F, Le Bruna-Ly V, et al. Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients.2013;1464-70.
    Open DOISearch in Google Scholar
  27. 27. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy.2014;424-33.
    Open DOISearch in Google Scholar
  28. 28. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy.2013;138-48.
    Open DOISearch in Google Scholar
  29. 29. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer.2013;213-23.
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.1515/raon-2015-0038 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 402 - 408
Submitted on: May 5, 2015
Accepted on: Jul 19, 2015
Published on: Nov 27, 2015
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
metastatic castration-resistant prostate cancer,
comorbidity,
chemotherapy
Related subjects:
Medicine,
Clinical medicine,
Radiology

© 2015 Andrej Zist, Eitan Amir, Alberto F. Ocana, Bostjan Seruga, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 49 (2015): Issue 4 (December 2015)
Previous article
Next article